seribantumab
elevation oncology
['seribantumab']
 tissue agnostic target seribantumab in pts with #nrg1 fusion cancers rr 33% (including 17% cr) with 92% disease control rate. efficacy seen across fusion partners. responses occurred early. median dor not reached #precisionmedicine #asco22 
Vivek Subbiah, MD, (@VivekSubbiah) #PrecisionMedicine Expert and Medical Oncologist, takes over our Twitter today to discuss #ASCO22.